Compugen (NASDAQ:CGEN) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Compugen (NASDAQ:CGEN) in a research report released on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $4.00 target price on the biotechnology company’s stock.

Several other research firms have also commented on CGEN. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Compugen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Compugen has an average rating of “Hold” and an average price target of $4.00.

Compugen Stock Performance

NASDAQ:CGEN opened at $1.72 on Wednesday. The firm has a 50-day simple moving average of $1.58 and a 200-day simple moving average of $1.58. Compugen has a one year low of $1.13 and a one year high of $2.66. The firm has a market cap of $138.32 million, a P/E ratio of -5.73 and a beta of 2.85.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company had revenue of $1.89 million for the quarter, compared to analyst estimates of $1.47 million. Compugen had a negative net margin of 400.10% and a negative return on equity of 53.60%. On average, research analysts predict that Compugen will post -0.03 EPS for the current fiscal year.

Institutional Trading of Compugen

A number of institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP increased its stake in Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 18,929 shares in the last quarter. Franklin Resources Inc. purchased a new position in Compugen in the 2nd quarter worth $56,000. Osaic Holdings Inc. lifted its position in Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 34,045 shares during the period. Raymond James Financial Inc. grew its stake in Compugen by 51.0% during the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 34,215 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in Compugen during the 2nd quarter valued at about $71,000. 12.22% of the stock is currently owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.